Skip to main content
. 1999 Nov;58(Suppl 1):I56–I60. doi: 10.1136/ard.58.2008.i56

Figure 6  .

Figure 6  

MMP-1 and MMP-3 levels are decreased after infliximab treatment in a randomised placebo controlled trial of infliximab in RA. MMP-1 and MMP-3 levels were determined in serum by a double antibody sandwich ELISA in placebo (circle) (n = 21), 1 mg/kg (diamond) (n = 19), 10 mg/kg (triangle) (n = 17) infliximab treated RA patients before infusion (day 0) and 7, 14, 21 and 28 days after infusion. Values are expressed relative to pre-infusion values (100%). Statistical analysis between the infliximab treated groups and placebo at day 7, 14, 21 and 28 was performed using the Mann-Whitney U test († = p < 0.05; †† = p < 0.01; ††† = p < 0.001). Reproduced with modification from Br J Rheumatol 1997;36:643-50 by kind permission of the editor.